TAK 875 (100 mg/day) versus TAK 875 (400 mg/day) in Japanese patients with type 2 diabetes mellitus
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2012
At a glance
- Drugs Fasiglifam (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Takeda
- 01 Mar 2012 Results published in Diabetes, Obesity and Metabolism.
- 03 Jul 2011 New trial record
- 28 Jun 2011 Pharmacokinetic/pharmacodynamic results (n=44) presented at the 71st Annual Scientific Sessions of the American Diabetes Association.